Skip to content

For Partners

Part of the world's largest curated database of clinical microRNA profiles

MiRXES is a world leader in applying microRNA detection technologies to the discovery of novel microRNA biomarkers and the development of clinical assays and other practical applications.

Starting with the Singapore Gastric Cancer Consortium in 2012, we have partnered with top academic research institutes and pharmaceutical companies worldwide.

Our research programmes span the biomedical, pharmaceutical, agri-biotech, and veterinary industries and include human diseases such as cancer, cardiovascular disease, and diabetes.

over

0

patient samples profiled globally.

over

0

patient samples to be profiled globally.

over

0

major pharma and academic partners globally.

over

0

cancer types studied

over

0

major diseases studied

Gastric Cancer

MiRXES’ fruitful collaboration with the Singapore Gastric Cancer Consortium and other researchers at the National University Hospital (NUH), Tan Tock Seng Hospital (TTSH), A*STAR’s Diagnostics Development Hub (DxD Hub) and Bioprocessing Technology Institute since 2012 has yielded GASTROClear, a CE-marked and Health Science Authority (HSA)-approved clinical microRNA assay that is the world’s first blood test for early detection of gastric cancer.

This partnership continues into post-market studies as the team studies the clinical utility and health economics of using GASTROClear as an in vitro diagnostic (IVD) and tool for gastric cancer screening.

We are also working with researchers worldwide, from the University of Tokyo and National Cancer Centre East in Japan to Yonsei Cancer Center in Korea, to develop gastric cancer microRNA biomarkers for prognosis, treatment-selection, and disease monitoring.

Read more

Lung Cancer

MiRXES has multiple research collaborations with academic and industry partners focused on lung cancer, the most common and also most deadly cancer worldwide.

We have completed a lung cancer biomarker discovery study of over 1,600 patients from Singapore, China, and Europe in collaboration with Zhejiang Cancer Hospital in China, and in 2018 started an ongoing strategic collaboration with Johnson & Johnson Innovation and Janssen Pharmaceutica to develop a novel lung cancer diagnostic test with the aim to improve the detection of early-stage disease.

We are currently lining up partners worldwide to start the world’s largest microRNA biomarker clinical study for early detection of lung cancer.

 

Heart Failure

MiRXES has extensive research collaborations in non-oncology fields where microRNA biomarkers may also help in diagnosis and prognosis of disease.

We have completed a research study that showed that combining a circulating microRNA assay with NT-proBNP, a commonly used biomarker for detection of heart failure, resulted in more accurate detection of heart failure. The research was led by Prof. Mark Richards and Dr Wong Lee Lee at the Cardiovascular Research Institute in Singapore, and included more than 30 clinicians and researchers from Singapore and New Zealand.

The results of the study were published in March 2019 in the Journal of the American College of Cardiology (2018 Impact Factor of 18.6). 

Read more

Diabetes

MiRXES research and development activities cover both basic and clinical research, with partners from both academic research institutes and large pharmaceutical companies.

We completed an exploratory microRNA biomarker discovery study for insulin resistance, a risk factor for prediabetes and type 2 diabetes. The study was done in partnership with Janssen Research & Development US and researchers at the National University of Singapore, A*STAR Institute of Molecular and Cell Biology, and National University Hospital.

The results of the study were published in April 2019 in the Frontiers in Physiology journal. 

Read more

 

MiRXES’ fruitful collaboration with the Singapore Gastric Cancer Consortium and other researchers at the National University Hospital (NUH), Tan Tock Seng Hospital (TTSH), A*STAR’s Diagnostics Development Hub (DxD Hub) and Bioprocessing Technology Institute since 2012 has yielded GASTROClear, a CE-marked and Health Science Authority (HSA)-approved clinical microRNA assay that is the world’s first blood test for early detection of gastric cancer.

This partnership continues into post-market studies as the team studies the clinical utility and health economics of using GASTROClear as an in vitro diagnostic (IVD) and tool for gastric cancer screening.

We are also working with researchers worldwide, from the University of Tokyo and National Cancer Centre East in Japan to Yonsei Cancer Center in Korea, to develop gastric cancer microRNA biomarkers for prognosis, treatment-selection, and disease monitoring.

Read more

Contact Us Today

For more information about any of our research or to explore partnerships!